Roivant to Present PHocus Study Results at ERS Congress 2026

GlobeNewswire··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Roivant and Pulmovant announced that topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease will be presented at the European Respiratory Society International Congress 2026 on Tuesday, September 8, 2026, at 12:15 CEST, followed by an investor call and webcast at 8:00 a.m. ET the same day. The presentation will be given by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant, a commercial-stage biopharmaceutical company, is developing mosliciguat as an inhaled sGC activator for this condition. The company will host the investor call to discuss the results, with details available on its website.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
Roivant Sciences Ltd
ROIV
▲ PositiveTechnologyrelevance

Roivant will present topline Phase 2 PHocus results for mosliciguat in PH-ILD at ERS Congress 2026, a clinical data readout for its pipeline asset.

Off-coverage companies 1

Pulmovant, Inc.Private▲ Positive
Technologyrelevance

Pulmovant, co-announcing with Roivant, is developing mosliciguat and its Phase 2 PHocus topline results will be presented at ERS Congress 2026.

© 2026 MarketIVNews